California State Teachers Retirement System Has $3.99 Million Position in Amicus Therapeutics, Inc. (FOLD)

California State Teachers Retirement System increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 4.1% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 264,569 shares of the biopharmaceutical company’s stock after acquiring an additional 10,340 shares during the period. California State Teachers Retirement System’s holdings in Amicus Therapeutics were worth $3,990,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. FMR LLC raised its position in Amicus Therapeutics by 3.4% in the 2nd quarter. FMR LLC now owns 21,437,508 shares of the biopharmaceutical company’s stock valued at $215,876,000 after purchasing an additional 705,153 shares during the last quarter. Redmile Group LLC raised its position in Amicus Therapeutics by 5.9% in the 2nd quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock valued at $121,282,000 after purchasing an additional 668,080 shares during the last quarter. Jennison Associates LLC raised its position in Amicus Therapeutics by 9.4% in the 3rd quarter. Jennison Associates LLC now owns 9,772,025 shares of the biopharmaceutical company’s stock valued at $147,362,000 after purchasing an additional 838,267 shares during the last quarter. Vanguard Group Inc. raised its position in Amicus Therapeutics by 5.0% in the 2nd quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock valued at $91,821,000 after purchasing an additional 430,486 shares during the last quarter. Finally, Palo Alto Investors LLC raised its position in Amicus Therapeutics by 0.7% in the 2nd quarter. Palo Alto Investors LLC now owns 7,940,788 shares of the biopharmaceutical company’s stock valued at $79,964,000 after purchasing an additional 57,800 shares during the last quarter.

Shares of Amicus Therapeutics, Inc. (FOLD) opened at $14.91 on Friday. The company has a market capitalization of $2,390.00, a price-to-earnings ratio of -8.15 and a beta of 1.72. Amicus Therapeutics, Inc. has a 52 week low of $5.07 and a 52 week high of $16.60. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). The firm had revenue of $10.90 million during the quarter, compared to analyst estimates of $9.02 million. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The firm’s quarterly revenue was up 419.0% on a year-over-year basis. During the same period last year, the business posted ($0.33) earnings per share. sell-side analysts predict that Amicus Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

In other news, insider Jay Barth sold 5,000 shares of Amicus Therapeutics stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $14.71, for a total value of $73,550.00. Following the completion of the sale, the insider now directly owns 69,184 shares of the company’s stock, valued at approximately $1,017,696.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Daphne Quimi sold 7,000 shares of Amicus Therapeutics stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total value of $99,750.00. The disclosure for this sale can be found here. Insiders sold a total of 826,114 shares of company stock valued at $11,791,184 over the last three months. Insiders own 3.40% of the company’s stock.

Several brokerages have issued reports on FOLD. BidaskClub upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Robert W. Baird reiterated an “outperform” rating and issued a $18.00 price objective (up previously from $16.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Leerink Swann reiterated a “buy” rating and issued a $20.00 price objective (up previously from $17.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Chardan Capital reiterated a “buy” rating and issued a $18.50 price objective (up previously from $16.50) on shares of Amicus Therapeutics in a research report on Thursday, October 5th. Finally, Zacks Investment Research downgraded Amicus Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, December 19th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $17.81.

TRADEMARK VIOLATION WARNING: “California State Teachers Retirement System Has $3.99 Million Position in Amicus Therapeutics, Inc. (FOLD)” was first published by Equities Focus and is owned by of Equities Focus. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.equitiesfocus.com/2018/01/07/california-state-teachers-retirement-system-has-3-99-million-position-in-amicus-therapeutics-inc-fold.html.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply